Structure’s obesity pill prompts 16.3% weight loss in Phase II
Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.
17 March 2026
17 March 2026
Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.